Corren 2016

Methods	Parallel, double‐blind
Participants	496 participants with moderate‐severe asthma (based on at least medium‐dose ICS, inadequate control ACQ ≥ 1.5) Main inclusion/exclusion criteria: ACQ‐7 score ≥ 1.5 maintenance treatment with medium‐dose ICS; maintenance OCS not allowed Age: reslizumab, mean 44.9; placebo, mean 45.1 Males: reslizumab, 137; placebo, 44 Baseline mean (SD) FEV1, % predicted: reslizumab, 66.8% placebo, 66.5% Allocation: to reslizumab, 398; to placebo, 98
Interventions	IV reslizumab 3.0 mg/kg or placebo once every 4 weeks (total of 4 doses)
Outcomes	Primary outcomes HRQoL (as measured by a validated questionnaire) Asthma exacerbation as defined by a hospital admission or treatment with oral corticosteroids Serious adverse events. Secondary outcomes FEV1 PEFR Asthma symptoms Adverse events/side effects Eosinophil counts in peripheral blood, sputum or bronchioalveolar lavage fluid
Notes	66 study locations across the USA Funding: Teva Branded Pharmaceutical Products R&D, Inc
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not stated, no clarification available from study authors
Allocation concealment (selection bias)	Unclear risk	Not stated, no clarification available from study authors
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	Dropouts comparable in each group (16/98, 16%, placebo vs 58/398, 15%, reslizumab)
Selective reporting (reporting bias)	Low risk	All primary and secondary outcomes reported with numbers, except blood eosinophil counts only shown as a chart